Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: A follow-up of patients in clinical remission

British Journal of Haematology

Volumn 99, Issue 1, 1997, Pages 64-75

  Engel, Heike ^a,c   Goodacre, Angela ^a   Keyhani, Afsaneh ^a   Jiang, Shuwei ^a   Van, Nguyen T ^a   Kimmel, Marek ^b   Sanchez Williams, Gisela ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b The NanoCarbon Center and Welch Institute for Advanced Materials   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acute myelogenous leukaemia; Fluorescence activated cell sorting; Fluorescence in situ hybridization; Minimal residual disease; Myelodysplastic syndrome

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION;

EID: 0030780127     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3323151.x     Document Type: Article

References (54)

1. Anastasi, J., Feng, J., Le Beau, M.M., Larson, R.A., Rowley, J.D. & Vardiman, J.W. (1993) Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood, 81, 1580.
2. Anastasi, J., Le Beau, M.M., Vardiman, J.W. & Westbrook, C.A. (1990) Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells using in-situ hybridization with a chromosome-specific probe. American Journal of Pathology, 136, 131-159.
3. Andreeff, M., Drach, J. & Tafuri, A. (1992) Interleukin-3 before and during idarubicin/Ara-C in acute myeloblastic leukemia. Blood, 80, 111a.
4. Andreeff, M., Leahy, J., Goodacre, A., Drach, D., Sanchez-Williams, G., Pinkel, D. & Drach, J. (1993) Minimal residual disease in acute myeloblastic leukemia (AML) and myelodysplastic syndromes (MDS): molecular cytogenetics predicts clinical relapse. Blood, 82, 36a.
5. Andreeff, M., Redner, A. & Thongprasert, S. (1985) Multiparameter flow cytometry for ploidy determination, proliferation and differentiation in acute leukemia: treatment effects and prognostic value. Tumor Aneuploidy (ed. by T. Buechner). p. 81. Springer, Berlin.
6. Baurmann, H., Cherif, D. & Berger, R. (1993) Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders. Leukemia, 7, 384-391.
7. Bendall, L.J., Daniel, A., Kortlepel, K. & Gottlieb, D.J. (1994) Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Experimental Hematology, 22, 1252-1260.
8. Bernasconi, P., Alessandrino, E.P., Boni, M., Bonfichi, M., Morra, E., Lazzarino, M., Campagnoli, C. & Astori, C. (1994) Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival, American Journal of Hematology, 46, 270-277.
9. Biondi, A., Rambaldi, A. & Pandolfi, P.P. (1992) Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood, 80, 492-497.
10. Campana, D. (1993) Detection of minimal residual disease in leukemia and lymphoma. Recent Advances in Hematology, 7, 21-34.
11. Campana, D. (1994a) Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry, 18, 68-74.
12. Campana, D. (1994b) Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results. International Journal of Clinical Laboratory Research, 24, 1-7.
13. Campana, D., Freitas, R.O. & Coustan-Smith, E. (1994) Detection of minimal residual disease with immunologic methods: technical developments and clinical implications. Leukemia and Lymphoma, 13, 31-34.
14. Casey, G., Rudzki, Z., Roberts, M., Hutchins, C. & Juttner, C. (1993) N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology, 25, 57-62.
15. Chang, K.S., Lu, J. & Wang, G. (1992) The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by polymerase chain reaction. Blood, 79, 554-558.
16. + malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia, 7, 853-858.
17. Delforge, M., Demuynck, H., Vandenberghe, P., Verhoef, G., Zachee, P., Duppen, V.V., Marijnen, P., Van den Berghe, H. & Boogaerts, M.A. (1995) Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood, 86, 3660-3667.
18. Drach, J., Drach, D., Glassl, H., Gattringer, C. & Huber, H. (1992) Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry, 13, 893-901.
19. Engel, H., Goodacre, A., Keyhani, A., Jiang, S., Van, N.T., Kimmel, M., Sanchez-Williams, G. & Andreeff, M. (1995) Detection of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in clinical remission by molecular cytogenetics. Blood, 86, 268a.
20. Estey, E.H., Kantarjian, H.M. & O'Brien, S. (1992a) Treatment of poor-prognosis newly-diagnosed AML or MDS with G-CSF prior to, during and following fludarabine and Ara-C (FLAG). Blood, 80, 112a.
21. Estey, E.H., Thall, P., Andreeff, M., Beran, M., Kantarjian, H.M., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C., Kornblau, S., Pierce, S., Freireich, E.J., Deisseroth, A.B. & Keating, M.J. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
22. Estey, E.J., Thall, P. & Kantarjian, H.M. (1992b) Treatment of newly-diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood, 79, 2246-2253.
23. Estrov, Z., Grunberger, T., Dulbe, I.D., Wang, Y.-P. & Freedman, M.H. (1986) Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. New England Journal of Medicine, 315, 538-542.
24. Evinger-Hodges, M.J., Spinolo, J.A., Spencer, V. Nieto, P. & Dicke, K.A. (1989) Detection of minimal residual disease in acute myelogenous leukemia by RNA-in situ hybridization. Bone Marrow Transplantation, 4, 13-15.
25. Foon, K.A. & Gale, R.P. (1992) Therapy of acute myelogenous leukemia. Blood Reviews, 6, 15-25.
26. Frankel, S.R., Baer, M.R., Stewart, C.C., Nettleton, A., Lawrence, D., Schiffer, C.A., Herzig, G.P. & Bloomfield, C.D. (1993) Relapse in AML is consistently detected by multiparameter flow cytometry (MFC) (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 12, A1015.
27. Freireich, E.J., Cork, A., Stass, S.A., McCredie, K.B., Keating, M.J., Estey, E.H., Kantarjian, H.M. & Trujillo, J.M. (1992) Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia, 6, 500-506.
28. Garson, O.M., Hagemejer, A. & Sakurari, M. (1989) Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genetics and Cytogenetics, 40, 197-202.
29. Gerhartz, H.H. & Schmetzer, H. (1990) Detection of minimal residual disease in acute myeloid leukemia. Leukemia, 4, 508-516.
30. Grimwade, D., Walker, H., Harrison, C., Oliver, F., Wheatley, K., Harrison, G., Gray, R., Hann, I., Stevens, R., Rees, J., Goldstone, A. & Burnett, A. (1996) Impact of diagnostic cytogenetics on outcome in AML: analysis of 1.613 patients entered into the UK MRC AML 10 trial. Blood, 88, 634a.
31. + subpopulations. Blood, 86, 2906-2912.
32. Hagenbeek, A. (1992) Minimal residual disease in leukemia: state of the art 1992. Leukemia, 6, 12-16.
33. Hann, I.M., Stevens, R.E., Goldstone, A.H., Rees, J.K.H., Wheatley, K., Gray, R.G. & Burnett, A.K. (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th trial (MRC 10). Blood, 89, 2311-2318.
34. Hochhaus, A., Lin, F., Reiter, A., Skladny, H., Mason, P.J., Van Ree, F., Shepard, P.C.A., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood, 87, 1549-1555.
35. Lo Cocco, F., Diverio, D. & Pandolli, P.P. (1992) Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet, 340, 1437-1438.
36. Mayer, R.J. (1990) Acute leukemias in adults: an overview of recent strategies. Journal of Cancer Research and Clinical Oncology, 116, 94-96.
37. +lin-) in acute leukemia. Blood, 86, 1139-1147.
38. Pasquali, E., Bernasconi, P., Casalone, R., Fraccaro, M., Bernasconi, C., Lazzarino, M., Morra, E., Alessandrino, E.P., Marchi, M.A. & Sanger, R. (1982) Pathogenetic significance of 'pure' monosomy 7 in myeloproliferative disorders: analysis of 14 cases. Human Genetics, 62, 40-51.
39. Pinkel, D., Straume, T. & Gray, J.W. (1986) Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization. Proceedings of the National Academy of Sciences of the United States of America, 83, 2934-2938.
40. Poddighe, P.J., Moesker, O., Smeets, D., Awwad, B.H., Ramaekers, F.C.S. & Hopman, A.H.N. (1991) Interphase cytogenetics of hematological cancer: comparison of classical karyotyping and in-situ hybridization using a panel of eleven chromosome specific DNA probes. Cancer Research, 51, 1959-1967.
41. Potter, M.N., Cross, N.C., van Dongen, J.J., Saglio, G., Oakhill, A., Bartram, C.R. & Goldman, J.M. (1993) Molecular evidence of minimal residual disease after treatment for leukemia and lymphoma: an updated meeting report and review. Leukemia, 7, 1302-1314.
42. Rees, J.K.H. (1993) Aspects of treatment of acute myeloid leukemia in adults. Current Opinion in Oncology, 5, 53-70.
43. Rees, J.K.H., Gray, R.G. & Wheatly, K. (1996) Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML 9 study. British Journal of Haematology, 94, 89-98.
44. Roberts, W.M., Estrov, Z., Ouspenskaia, M.V., Johnston, D.A., McClain, K.L. & Zipf, T.F. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 336, 317-323.
45. Stass, S.A., Mirro, J., Melvin, S., Pui, C.H., Murphy, S.B. & Williams, D. (1984) Lineage switch in acute leukemia. Blood, 64, 701-706.
46. Terstappen, L.W.M.M., Safford, M., Koenemann, S., Loken, M.R., Zurlutter, K., Buechner, T., Hiddemann, W. & Wörmann, B. (1991) Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia, 5, 70-80.
47. Thomas, X., Campos, L. & Archimbaud, E. (1992) Surface marker expression in acute myeloid leukaemia at first relapse. British Journal of Haematology 81, 40-44.
48. Tobal, K. & Liu Yin, J.A. (1996) Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood, 88, 3704-3709.
49. Van der Leiv, N., Poddighe, P., Hopman, A. & De Witte, T. (1991) Cytogenetic studies of progenitor cell origin by in situ hybridization (ISH) in patients with acute myeolid leukemia (AML) (meeting abstract). Experimental Hematology, 99, 530.
50. Van Dongen, J.M., Breit, T.M., Adriaansen, H.J., Beishuizen, A. & Hooijkaas, H. (1992) Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia, 6, 47-59.
51. Vogler, W.R. (1992) Strategies in the treatment of acute myelogenous leukemia. Leukemia Research, 16, 1143-1153.
52. Wheatley, K., Burnett, A.K., Goldstone, A.H., Hann, I.M., Stevens, R.F., Rees, J.K.H. & Gray, R.G. (1996) Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukaemia (AML) in the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood, 88, 214a.
53. Wörmann, B. (1993) Implications of detection of minimal residual diseae. Current Opinion in Oncology, 5, 3-12.
54. Zhao, L., Chang, K.S., Estey, E.H., Hayes, K., Deisseroth, A.B. & Liang, J.C. (1995). Detection of residual leukemic cells in patients with acute promyelocytic leukemia by fluorescence in situ hybridization: potential for predicting relapse. Blood, 85, 495-499.